You are here

What next for Mental Health in Insurance?

Wednesday 1 December 2021 11:30 - 12:30

Content will be aimed at all actuaries looking to understand the issues surrounding mental health in insurance and in particular those looking to ensure products and processes widen access for, and are most useful to, those experiencing periods of poor mental health.

The national conversation around mental health is working to destigmatise talking about mental health conditions. We consider what the issues are for actuaries faced with in ensuring access for those with a history of poor mental health to insurance, how we make our processes easy to navigate for those with mental health conditions and avoid causing further distress and what product development ideas may be opened up by the increased amount of data in this space. This session will include an introduction from the IFoA mental health working party outlining the work they are doing in this area and what to expect from them over the coming year.


Fyona Murphy

Fyona is a Life Consultant at Hymans Robertson’s Insurance and Financial Services practice where she splits her time between supporting clients with product development and digital tooling and risk and capital management with a focus on with-profits business. Fyona is also a member of the IFoA Mental Health working party and ILAG protection groups.


Maryse Nashime

Maryse is a Senior Actuary at PartnerRe. She has worked in the Life (re)Insurance Industry for 10 years and is a qualified actuary from both the Society of Actuaries (SOA) and the Canadian Institute of Actuaries (CIA). She currently works as a product and project developments actuary, supporting pricing functions across Europe and Latin America, and prior to that as a dedicated pricing actuary for Canada and the US. Maryse is a member of the IFoA Mental Health working party.


Dr Rajeev Dhar

Dr. Dhar has held various clinic and leadership roles as a Consultant Psychiatrist in the NHS and the private and corporate sector; this has included as a Clinical Director and a Board member for NHS clinical commissioning boards. He advises the corporate sector on a range of areas including mental health in the work place and its impact on performance management and leadership; decision making as well as health and wellbeing. He is dually qualified as a Doctor and non practising Barrister and has an MBA from Warwick Business School. He has an interest in the use of technology and AI within the health care sector and for improving mental health outcomes.

He has also been a member of the Access To Insurance Working Group; an advisor to the Covid 19 Behavioural Change Unit of NHS England, the ISC Neurodiversity Working Group and secretary to the exec committee of the occupational psychiatry group at the Royal College of Psychiatry. He is also a senior medicolegal expert for the purposes of employment law cases. 


Mohamed Elsheemy

Mohamed is a Medicine Access Analyst at the Commercial Medicine Directorate in NHSE&I. He supports the commercial activity of new innovative drugs at the NHS in England, working for a commercial team that negotiates with pharma companies to agree commercial arrangements, and promoting innovation. His experience in the health and social care space, varied between working in academia, public health and in private health insurance. In 2018, he contributed to the development of a national framework for pricing the Children and Young People Mental Health (CYPMH) services.
Currently Mohamed is a member of the IFoA committee for Health and Care Lifelong Learning. He is also a member of several IFoA health and care working parties.



Event organiser

Contact Events Team for more information.

0207 632 1498